{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T21:21:28Z","timestamp":1761859288032,"version":"build-2065373602"},"reference-count":19,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.pathol.2022.02.011","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T07:40:15Z","timestamp":1653291615000},"page":"763-767","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bone marrow fibrosis impact on response to azacitidine in myelodysplastic syndromes"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0241-2768","authenticated-orcid":false,"given":"Roya","family":"Shahidi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhajir","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Archana","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4310-235X","authenticated-orcid":false,"given":"Jessica","family":"Heenan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5605-883X","authenticated-orcid":false,"given":"Sam","family":"Hitchins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2022.02.011_bib1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41408-018-0085-4","article-title":"Myelodysplastic syndromes current treatment algorithm 2018","volume":"8","author":"Steensma","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.pathol.2022.02.011_bib2","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.mayocp.2015.08.022","article-title":"Primary myelodysplastic syndromes: the Mayo Clinic experience with 1000 patients","volume":"90","author":"Gangat","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.pathol.2022.02.011_bib3","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1200\/JCO.2008.18.2246","article-title":"Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes","volume":"27","author":"Della Porta","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2022.02.011_bib4","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/modpathol.2013.187","article-title":"Bone marrow fibrosis in patients with primary myelodysplastic syndromes has prognostic value using current therapies and new risk stratification systems","volume":"27","author":"Fu","year":"2014","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2022.02.011_bib5","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1365-2141.1991.tb04411.x","article-title":"Myelodysplastic syndrome with increased marrow fibrosis: a distinct clinico-pathological entity","volume":"78","author":"Lambertenghi-Deliliers","year":"1991","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pathol.2022.02.011_bib6","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1385\/MO:21:4:325","article-title":"Myelofibrosis in primary myelodysplastic syndromes: clinical and biological significance","volume":"21","author":"Marisavljevic","year":"2004","journal-title":"Med Oncol"},{"key":"10.1016\/j.pathol.2022.02.011_bib7","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1600-0609.1992.tb01587.x","article-title":"Myelofibrosis in primary myelodysplastic syndromes: a retrospective study of 352 patients","volume":"48","author":"Maschek","year":"1992","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.pathol.2022.02.011_bib8","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/1097-0142(19910701)68:1<178::AID-CNCR2820680131>3.0.CO;2-Q","article-title":"Clinical and cytogenetic characteristics of myelodysplastic syndromes developing myelofibrosis","volume":"68","author":"Ohyashiki","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.pathol.2022.02.011_bib9","doi-asserted-by":"crossref","first-page":"30492","DOI":"10.18632\/oncotarget.9026","article-title":"Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis","volume":"7","author":"Ramos","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.pathol.2022.02.011_bib10","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2022.02.011_bib11","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.pathol.2022.02.011_bib12","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1182\/blood-2019-131881","article-title":"editors. Comparative analysis for effectiveness of azacitidine versus decitabine in acute myeloid leukemia and myelodysplastic syndromes with marrow fibrosis: a single institution experience","volume":"134","author":"Ebaid","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2022.02.011_bib13","doi-asserted-by":"crossref","first-page":"5524","DOI":"10.1182\/blood.V128.22.5524.5524","article-title":"editors. The role of marrow fibrosis in the prognosis and treatment of myelodysplastic syndromes: a single center retrospective study","volume":"28","author":"Groarke","year":"2016","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.pathol.2022.02.011_bib14","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1182\/blood.V128.22.4339.4339","article-title":"editors. Impact of bone marrow fibrosis in MDS patients treated with azacitidine","volume":"128","author":"Hammond","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2022.02.011_bib15","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1053\/j.seminhematol.2018.02.005","article-title":"Bone marrow fibrosis and early hematological response as predictors of poor outcome in azacitidine treated high risk-patients with myelodysplastic syndromes or acute myeloid leukemia","volume":"55","author":"Reda","year":"2018","journal-title":"Semin Hematol"},{"key":"10.1016\/j.pathol.2022.02.011_bib16","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2022.02.011_bib17","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pathol.2022.02.011_bib18","first-page":"1128","article-title":"European consensus on grading bone marrow fibrosis and assessment of cellularity","volume":"90","author":"Thiele","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.pathol.2022.02.011_bib19","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1002\/ajh.24901","article-title":"Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R","volume":"92","author":"Tefferi","year":"2017","journal-title":"Am J Hematol"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302522001362?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302522001362?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T16:28:55Z","timestamp":1758472135000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031302522001362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0031302522001362"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2022.02.011","relation":{},"ISSN":["0031-3025"],"issn-type":[{"type":"print","value":"0031-3025"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bone marrow fibrosis impact on response to azacitidine in myelodysplastic syndromes","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2022.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}